Clinical trials: SARS-COV-2 Infections
Coronavirus Disease (COVID-19)
Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001)
This study aims to evaluate the safety, tolerability and efficacy of molnupiravir (MK-4482) compared to placebo. The primary hypothesis is that molnupiravir is superior to placebo as assessed by the rate of sustained recovery…
- Trial name
- NCT04575584
- Testing
- Molnupiravir
- Where
- 89 sites in United States, Brazil and 15 more
- Volunteers
- 304 people
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Trial name
- NCT04486313
- Testing
- Nitazoxanide, Vitamin Super B-Complex
- Where
- 2 sites in United States
- Volunteers
- 935 people
- Sponsor
- Romark Laboratories L.C.
COVID-19 Drug Treatment
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy.
- Trial name
- NCT04381884
- Testing
- IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
- Where
- 3 sites in Argentina
- Volunteers
- 45 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
SARS-CoV Infection
Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection
This is a double-blinded, placebo-controlled parallel, phase II clinical efficacy study evaluating Nitric Oxide Nasal Irrigation (NONI) for the treatment of COVID-19 in individuals with mild COVID-19 Infection.
- Trial name
- NCT04443868
- Testing
- Nitric Oxide-Releasing Drug
- Sponsor
- Sanotize Research and Development corp.
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Covid19
Clinical Study Spartan COVID-19 V2 System (Canada Alternate)
This multicentre prospective study will enroll a sufficient number of patients to afford approximately 30 positives and > 30 negatives (as determined by the SOC - Comparator method) in the United States and/or Canada.
- Trial name
- NCT04628208
- Testing
- Spartan COVID-19 v2 System
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- Spartan Bioscience Inc.
COVID-19, COVID-19 Vaccine
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine
A multicenter, randomized, double-blind, active comparator, non-inferiority, multicenter IIb clinical trial to compare the safety and immunogenicity of two dose levels of the MCTI CIMATEC HDT RNA Vaccine against two authorized…
- Trial name
- NCT05542693
- Testing
- RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Respiratory Disease
Analysis of Vital Signs in Patients With COVID-19
This project will use data obtained from a proprietary vision-based patient monitoring and management system (OxeVision) for measuring heart rate and respiratory rate which is in clinical use at the Coventry and Warwickshire…
- Trial name
- NCT04927078
- Testing
- Observation of breathing pattern
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Oxehealth Limited
SARS-CoV-2 Infection
Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2
If a treated cancer patient cannot make antibodies to a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Emergency Use Authorization (EUA) or approved vaccine, their risk for infection and its sequelae are…
- Trial name
- NCT05438498
- Testing
- Evusheld (tixagevimab+cilgavimab) IM or IV
- Where
- 40 sites in United States
- Volunteers
- 550 people
- Sponsor
- MediMergent, LLC
COVID-19
SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)
Randomized, double-blind, placebo-controlled, multicenter phase II clinical study of SHEN211 tablets
- Trial name
- NCT06288893
- Testing
- SHEN211 Tablets
- Where
- China
- Volunteers
- 30 people
- Sponsor
- JKT Biopharma Co., Ltd.
Covid19
Dräger COVID-19 Antigen Test Clinical Performance Study
The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens.
- Trial name
- NCT04698993
- Testing
- Dräger Antigen Test SARS-CoV-2
- Where
- Germany
- Volunteers
- 388 people
- Sponsor
- Drägerwerk AG & Co. KGaA
Post-COVID-19 Condition, Post-COVID Condition
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
REGENECYTE® (HPC, Cord Blood (Hematopoietic Progenitor Cell, Cord Blood)) for treatment in patients with post-COVID.
- Conditions
- Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID
- Trial name
- NCT07332338
- Testing
- REGENECYTE®
- Where
- 2 sites in United States
- Sponsor
- StemCyte, Inc.
Respiratory Infection, Pneumonia
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
The main objectives of the trial are to assess the efficacy and safety of trimodulin as adjunctive treatment to standard of care (SoC) compared to placebo plus SoC in adult hospitalized subjects with non-severe community-acquired…
- Conditions
- Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome
- Trial name
- TRICOVID (NCT05531149)
- Testing
- Trimodulin
- Where
- 64 sites in Argentina, Austria and 12 more
- Volunteers
- 107 people
- Sponsor
- Biotest
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
COVID-19, Upper Respiratory Tract Infections
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIX™ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
TAFFIX is a nasal powder spray that immediately creates a protective acidic barrier on the nasal mucosa against infection by inhaled viruses. The protective barrier lasts 5 hours.
- Trial name
- NCT05252468
- Testing
- TaffiX™
- Where
- Bulgaria
- Volunteers
- 693 people, healthy volunteers welcome
- Sponsor
- Nasus Pharma
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
A Study to Learn How Paxlovid [Nirmatrelvir-ritonavir/PF-07321332] Works in COVID-19 Patients Who Are Elderly or Have Medical Conditions.
The purpose of this study is to learn about the effects of the study medicine called Paxlovid [nirmatrelvir-ritonavir/PF-07321332], for the potential treatment of COVID-19.
- Trial name
- NCT07261085
- Testing
- nirmatrelvir-ritonavir, No treatment
- Where
- United States
- Volunteers
- 99,000 people
- Sponsor
- Pfizer
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.